PRE News & Events

Prenetics Global announced the launch of Daily Ultimate Essentials PRO. Alongside the reformulated product, Prenetics is also introducing two new flavours - Mango + Passionfruit and Lemon + Orange - expanding the range to meet growing consumer demand for variety. Danny Yeung, Chief Executive Officer and Co-Founder of Prenetics, commented: "When we launched Daily Ultimate Essentials, we set out to create the most comprehensive daily health formula on the market. With PRO, we're raising that bar again. The addition of premium ingredients like saffron extract, the massive increase in key nutrient dosages, and the introduction of Mango + Passionfruit and Lemon + Orange flavours reflect our commitment to continuous improvement and listening to our community. And we're doing all of this at no extra cost - the PRO formula is available at the same price for both new and existing customers, because better health should be accessible to everyone."

Prenetics Global (PRE) announced the completion of the sale of its 35% equity interest in Insighta to Tencent (TCEHY) for total cash consideration of $70M. The transaction provides a substantial and immediate increase in Prenetics' cash resources, further strengthening the Company's financial position as it sharpens its focus on the global expansion of IM8, its flagship consumer health brand. The completion of the Insighta sale transaction with Tencent delivers $70M in new cash proceeds to Prenetics, of which $69M was received on February 13, 2026 with $1M held in escrow, materially enhancing the Company's liquidity and financial flexibility.

Reports Q4 revenue $36.56M, consensus $33.43M. Danny Yeung, CEO, commented: "2025 was a defining year for Prenetics-one in which we proved both the strength and scalability of IM8's business model. In just twelve months, IM8 reached $120M in annualized recurring revenue, an achievement that is virtually unprecedented in consumer health. This performance was powered by strong unit economics, a rapidly expanding global footprint, and deep customer engagement. Our transition towards quarterly subscriptions has delivered a meaningful acceleration in performance, with new blended average order value reaching approximately $233 in 2026. This strategy strengthens cash flow, enhances customer lifetime value, and supports efficient scaling. Importantly, we expect to approximately triple IM8 revenue in 2026 compared to 2025, while targeting an adjusted EBITDA loss broadly similar to 2024 and 2025. This demonstrates the operating leverage inherent in our model, and we see a clear path to achieving adjusted EBITDA profitability by the fourth quarter of 2027. With the completed sale of our Insighta stake to Tencent, our total adjusted liquidity stands at approximately $171M as of February 15, 2026 with zero debt. This provides substantial financial capacity to invest in IM8's next phase of global growth. We are confidently reaffirming our 2026 IM8 revenue guidance of $180M to $200 million, with a path toward $250 million to $300M in ARR by the end of 2026. IM8 is rapidly becoming a global, category-defining health brand-and this is only the beginning."